solutions for pharmaceutical manufacturers who participate in the Medicaid Drug Rebate Program and pay too much because of 340b duplicate discounts

Drug Pricing: Tech Start-Up Provides Solutions for Drug Manufacturers Subject to 340B Duplicate Discounts

The extent to which 340B covered entities receive duplicate discounts from pharmaceutical manufacturers who take part in the Medicaid Drug Rebate Program (MDRP) is widely documented.

The Medicaid Exclusion File

The Health Resources and Services Administration (HRSA) established the 340B Medicaid Exclusion File (MEF) as The mechanism to aid 340B covered entities and states to prevent duplicate discounts for drugs subject to Medicaid rebates.

But in terms of efficacy, the MEF is insufficient in mitigating duplicate discounts. An estimated $2 billion in improper rebate payments are paid by pharmaceutical manufacturers — and received by 340B covered entities — on an annual basis. Continue reading “Drug Pricing: Tech Start-Up Provides Solutions for Drug Manufacturers Subject to 340B Duplicate Discounts”